NMTRQ (9 Meters Biopharma) Forward Dividend Yield %: 0.00% (As of Jul. 06, 2026)


What is 9 Meters Biopharma Forward Dividend Yield %?

9 Meters Biopharma NMTRQ -90.00% Forward Dividend Yield % is 0.00% as of Jul. 06, 2026.

As of today (2026-07-06), the Forward Annual Dividend Yield of 9 Meters Biopharma is 0.00%.

As of today (2026-07-06), the Trailing Annual Dividend Yield of 9 Meters Biopharma is 0.00%.

NMTRQ's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.265
* Ranked among companies with meaningful Forward Dividend Yield % only.

9 Meters Biopharma's Dividends per Share for the three months ended in Mar. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

9 Meters Biopharma  (OTCPK:NMTRQ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

9 Meters Biopharma Forward Dividend Yield % Related Terms

NMTRQ vs USRM, NOVNQ, ONCSQ: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, 9 Meters Biopharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

9 Meters Biopharma Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Forward Dividend Yield % falls into.


9 Meters Biopharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
9 Meters Biopharma (NMTRQ) has a Forward Dividend Yield % of 0.00% as of Jul. 06, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on 9 Meters Biopharma and its competitors.
Is 9 Meters Biopharma's Forward Dividend Yield % too high?
9 Meters Biopharma's current Forward Dividend Yield % is 0.00%.
How does 9 Meters Biopharma's Forward Dividend Yield % compare to USRM and NOVNQ?
9 Meters Biopharma's Forward Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Forward Dividend Yield % is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.27, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on 9 Meters Biopharma and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 9 Meters Biopharma's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 9 Meters Biopharma stock overvalued right now?
9 Meters Biopharma (NMTRQ) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For 9 Meters Biopharma (NMTRQ), the current Forward Dividend Yield % is 0.00% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

9 Meters Biopharma Business Description

Address 4509 Creedmoor Road, Suite 600, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Its pipeline includes vurolenatide, a proprietary Phase 3 long-acting glucagon-like-peptide 1 (GLP-1) agonist for short bowel syndrome (SBS) and a robust pipeline of early-stage candidates for undisclosed rare diseases and/or unmet needs.